A Phase 3b Open-Label Extension of Study B23CS (ARENA 2) Evaluating the Continued Safety and Efficacy of ADV7103 in Subjects With Primary Distal Renal Tubular Acidosis (ARENA 2 Open-label Extension Study) - ARENA 2 Open-label Extension Study

Advicenne SA0 个研究点目标入组 40 人开始时间: 2019年9月11日最近更新: 2020年5月4日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Advicenne SA
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Inclusion criteria for subjects who did not participate in Study B23CS:
•1.Female or male subjects = 65 years of age at time of consent with the following stipulations:
•a.Subjects = 6 months of age must reside in Europe
•b.Subjects < 6 months of age may reside in the United States, Canada, or Europe and must be clinically stable as determined in consultation with the Sponsor and Medical Monitor;
•2.Subjects < 6 months of age must be able to swallow (not suck) solid food without difficulty in the judgment of the Investigator;
•3.Subject presents with a previous diagnosis of primary dRTA: the diagnosis duration must be reviewed by the Medical Monitor for subjects < 6 months of age, at least 4 months duration for subjects > 6 months and < 12 years of age, and at least one year for subjects = 12 years of age, based on documented history of non-anion gap, hyperchloremic, hypokalemic metabolic acidosis;
•4.Subject = 6 months of age requires = 0.9 mEq/kg/day of alkali therapy to maintain serum bicarbonate levels above the LLN for the laboratory providing results (subject < 6 months of age may be started on ADV7103 dose deemed appropriate by Investigator in consultation with Medical Monitor);
•5.Urine pH > 5.5 and serum bicarbonate > 18 mEq/L for subjects = 4 years old or > 17 mEq/L for subjects < 4 years old on alkali therapy and potassium supplementation (if indicated) on at least one occasion for each within 6 months prior to the initial study visit (a subject < 6 months old may enter the study solely on the basis of a diagnosis of non anion gap, hyperchloremic, hypokalemic metabolic acidosis after review by the Medical Monitor);
•6.European subjects must be included in a social health insurance system and/or in compliance with the recommendations of the national law in force relating to biomedical research;
•7.Subject or parent/guardian is willing and able to understand and sign informed consent and willing to comply with protocol instructions; child assent when appropriate; and
•8.Female subjects of childbearing potential and non sterilized males must use at least one of the following acceptable birth control methods from informed consent through 7 days after the last dose of study product:
•a.Double barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository)
•b.Established use of oral, injectable, or implanted hormonal methods of contraception
•c.Placement of an intrauterine device or intrauterine system
•Abstinence may be used in place of an acceptable contraceptive regimen. Females of childbearing potential are those who have reached the onset of menarche and are not postmenopausal (= 1 year without menses prior to the initial study visit)], surgically sterile, or status post hysterectomy (= 1 month prior to the initial study visit). Pregnancy testing is not required for premenarchal females who are abstinent. From informed consent through 7 days after the last dose of study product, female subjects of childbearing potential must agree to refrain from egg donation and male subjects of age must agree to refrain from sperm donation.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 22
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 9
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 3

排除标准

•Exclusion criteria for subjects who did not participate in Study B23CS:
•1.Female subject who is pregnant or lactating or has plans for pregnancy during the study;
•2.Subject has evidence of proximal tubule dysfunction (eg, hypophosphatemia, low serum uric acid, glycosuria, or amino aciduria) unless the subject is < 6 months of age;
•3.Subject presents with another diagnosed condition as a potential etiology for her/his dRTA (eg, systemic lupus erythematosus, Sjogren's syndrome);
•4.Subject requires therapy with potassium sparing diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, trimethoprim, drospirenone and other progestins, nephrotoxic antibiotics, penicillins, tacrolimus, or medications known to delay gastric emptying or otherwise interfere with absorption of study product;
•5.Subject has evidence of obstructive uropathy or other findings on renal ultrasound expected to require intervention during the course of the study;
•6.Subject has any of the following laboratory abnormalities:
•a.AST and/or ALT > 1.5x upper limit of normal (ULN)
•b.Serum potassium > 5.0 mEq/L or hypokalemia accompanied by clinical symptoms (eg, muscle cramps) or significant ECG changes (eg, T wave depression, U wave elevation)
•c.Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 (according to the modified Schwartz formula for children and Chronic Kidney Disease – Epidemiology Collaboration [CKD-EPI] formula for adults). For subjects 14 to 17 years of age with an eGFR < 60 mL/min/1.73 m2 via the modified Schwartz formula, the eGFR may be recalculated using the pediatric cystatin C equation if there is a cystatin C result less than 120 days old and serum creatinine has not changed by more than 20% over the last
•120 days. If cystatin C results are not available, the qualifying eGFR can be calculated by using both the modified Schwartz and CKD EPI methods and averaging these values to obtain the eGFR.
•d.Total bilirubin > ULN, except with known Gilbert's disease.
•7.Subject has been hospitalized or had outpatient surgery (other than minor skin and dRTA disease-related procedures or ear tube placement) in the past 6 months or is planning surgery in the next 6 months;
•8.In the opinion of the Investigator, the subject has a major medical or psychiatric condition (eg, significant cardiac disease, schizophrenia) or an unstable condition (eg, uncontrolled hypertension, asthma, diabetes, hypercholesterolemia, or cardiac disease) that would potentially interfere with the subject safely completing the study;
•9.In the opinion of the Investigator, the subject has a history of difficulty taking oral medication and/or conditions that may hamper absorption of the study product (eg, any difficulty of swallowing, malabsorption, delayed gastric emptying, esophageal compression, intestinal obstruction, or other chronic gastrointestinal disease);
•10.Self-reported or parent/guardian reported alcohol abuse or drug abuse within the past 12 months;
•11.Subject is a solid organ or bone marrow transplant recipient;
•12.Subject has a history of malignancy within 5 years prior to the screening visit, except for localized skin or cervical carcinoma; or
•13.Subject is known to have an allergy to any ADV7103 constituents.

研究者

发起方

Advicenne SA

相似试验

进行中（未招募）

不适用

An Open-Label Extension of the Phase III Study CL-758010 with Alzhemed™ in Patients with Alzheimer’s Disease.Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disorder, characterized by gradual cognitive decline, abnormal behaviour, and personality changes.MedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's disease

EUCTR2006-006490-24-SEeurochem Inc650

进行中（未招募）

不适用

EUCTR2006-006490-24-FReurochem Inc650

进行中（未招募）

不适用

EUCTR2006-006490-24-BEeurochem Inc650

进行中（未招募）

不适用

EUCTR2006-006490-24-GBeurochem Inc650

进行中（未招募）

1 期

A clinical study to assess the long-term safety and efficacy of idebenone treatment in patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study.

EUCTR2017-004279-30-DESanthera Pharmaceuticals (Switzerland) Limited266